LIVER CANCER: NOVEL ADVANCEMENTS IN 2017

FRIDAY, DECEMBER 15th, 2017

Icahn School of Medicine at Mount Sinai
Kenneth L. Davis, MD Auditorium, 2nd floor
Hess Center for Science and Medicine
1470 Madison Avenue (Between 101st and 102nd streets)
New York, NY

Program Director
JOSEP M. LLOVET, MD, PhD
Professor of Medicine
Co-Director, Mount Sinai Liver Cancer Program

Sponsored by
Mount Sinai Liver Cancer Program

1st NCI recognized Liver Cancer Program in the U.S.

www.icahn.mssm.edu/cme/courses
Location
Icahn School of Medicine at Mount Sinai
Kenneth L. Davis, MD Auditorium, 2nd floor, Hess Center for Science and Medicine, 1470 Madison Avenue (Between 101st and 102nd Streets) New York, NY
Directions and Parking: www.icahn.mssm.edu/about/visiting

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Program Director
JOSEP M. LLOVET, MD, PhD, Professor of Medicine
Co-Director, Mount Sinai Liver Cancer Program

Program Chairs
SCOTT L. FRIEDMAN, MD, Professor of Medicine, Dean for Therapeutic Discovery
Co-Director, Mount Sinai Liver Cancer Program
MYRON SCHWARTZ, MD, Professor of Surgery, Director of Liver Surgery
SAMUEL WAXMAN, MD, Professor of Medicine, Department of Hematology and Medical Oncology, Department of Oncological Sciences

Target Audience
Hepatologists and Gastroenterologists, Oncologists, Surgeons, Radiologists, Pathologists and Basic Scientists interested in liver cancer from the New York Area and beyond.

Activity Description
This conference will assemble multidisciplinary experts on chronic liver diseases, hepatocellular carcinoma (HCC) and cholangiocarcinoma (iCCA) from the Mount Sinai Liver Cancer Program and two outstanding invited lecturers. The meeting is intended to provide a summary of the state-of-the-art knowledge of the novel advancements reported in 2017 on the pathogenesis and clinical management of liver cancer, including the research conducted in Mount Sinai.

Activity Learning Objectives
• Review the impact of anti-viral therapies for HCV on HCC development.
• Evaluate novel opportunities for prevention of liver cancer.
• Describe the current surgical and medical management of HCC and iCCA.
• Describe the breakthroughs in HCC management in 2017.

Registration Fee
International Attendees $100
All Others Complimentary
Register Online at: www.icahn.mssm.edu/cme/courses

Credit Designation (CME)
The Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation
The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Verification of Attendance
Verification of attendance will be provided to all professionals.

Special Needs
The Icahn School of Medicine at Mount Sinai is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you require special accommodations please contact the Page and William Black Post-Graduate School of Medicine at 212-731-7950.

Acknowledgment
This activity is made possible in part by educational grants from:
Bayer HealthCare, BTG International, Bristol-Myers Squibb, Eisai
FRIDAY, DECEMBER 15, 2017

PROGRAM

8:30 – 9:00am  Registration

9:00 – 9:10am  Welcome and Opening
Ramon Parsons, MD, PhD
Director, Tisch Cancer Institute

9:10 – 9:40am  Achievements of Mount Sinai Liver Cancer Program 2005-17
Josep M. Llovet, MD, PhD
Mount Sinai Liver Cancer Program, Division of Liver Diseases

9:40 – 10:20am  Hans Popper Lecture:
Introduction: Josep M. Llovet, MD, PhD
Mount Sinai Liver Cancer Program, Division of Liver Diseases
Molecular Therapies for Neuroendocrine Tumors: Lessons Learned
Marianne Pavel, MD
Universitatsklinikum Erlangen, Germany

10:20 – 10:30am  Coffee Break

10:30 – 11:50am  EPIDEMIOLOGY, PATHOGENESIS AND PREVENTION OF HCC
Chairman: Scott Friedman, MD, Mount Sinai Liver Cancer Program, Division of Liver Diseases

10:30 – 10:50am  Impact of DAA Treatment for HCV on HCC Development
Douglas T. Dieterich, MD
Division of Liver Diseases

10:50 – 11:10am  Surveillance for HCC, When and Why
Behnam Saberi, MD
Mount Sinai Liver Cancer Program, Division of Liver Diseases

11:10 – 11:30am  Role of Stellate Cells in Hepatocarcinogenesis
Scott L. Friedman, MD
Mount Sinai Liver Cancer Program, Division of Liver Diseases

11:30 – 11:50am  Key Targets for Chemoprevention in HCC: What To Do Now
Yujin Hoshida, MD, PhD
Mount Sinai Liver Cancer Program, Division of Liver Diseases

11:50 – 12:30pm  Lunch

12:30 – 1:50pm  MANAGEMENT OF LIVER CANCER (I)
Chairman: Myron Schwartz, MD, Mount Sinai Liver Cancer Program, Department of Surgery

Diagnosis, Guidelines and Surgery

12:30 – 12:50pm  Pathological Classification of Liver Cancer
Swan N. Thung, MD
Mount Sinai Liver Cancer Program, Department of Pathology
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Affiliation(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:50 – 1:10pm</td>
<td>MRI for HCC Surveillance: Preliminary Results</td>
<td>Sara Lewis, MD</td>
<td>Department of Radiology, Translational and Molecular Imaging Institute</td>
</tr>
<tr>
<td>1:10 – 1:30pm</td>
<td>What is New in the Surgical Management of Liver Cancer?</td>
<td>Myron Schwartz, MD</td>
<td>Mount Sinai Liver Cancer Program, Department of Surgery</td>
</tr>
<tr>
<td>1:30 – 1:50pm</td>
<td>Chemoembolization and Radioembolization in HCC Management: New Trials</td>
<td>Edward Kim, MD</td>
<td>Mount Sinai Liver Cancer Program, Department of Radiology, Department of Surgery</td>
</tr>
<tr>
<td>1:50 – 2:10pm</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:10 – 2:30pm</td>
<td>MANAGEMENT OF LIVER CANCER (II)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:10 – 2:50pm</td>
<td>State-of-the-Art Lecture: AASLD 2017 Guidelines for Management of HCC</td>
<td>Jorge Marrero, MD</td>
<td>UT Southwestern, Dallas, TX</td>
</tr>
<tr>
<td>2:50 – 3:10pm</td>
<td>Role of SBRT in the Treatment of HCC</td>
<td>Michael Buckstein, MD</td>
<td>Mount Sinai Liver Cancer Program, Department of Radiation Oncology</td>
</tr>
<tr>
<td>3:10 – 3:30pm</td>
<td>Positive Lenvatinib and Regorafenib Data in HCC Management</td>
<td>Josep M Llovet, MD</td>
<td>Mount Sinai Liver Cancer Program, Division of Liver Diseases</td>
</tr>
<tr>
<td>3:30 – 3:50pm</td>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:50 – 4:10pm</td>
<td>NOVEL CONCEPTS IN HEPATOCARCINOGENESIS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:50 – 4:10pm</td>
<td>Immune Subclasses of HCC</td>
<td>Daniela Sia, PhD</td>
<td>Mount Sinai Liver Cancer Program, Division of Liver Diseases</td>
</tr>
<tr>
<td>4:10 – 4:30pm</td>
<td>Linking Fibrosis, Autophagy and HCC</td>
<td>Youngmin Lee, MD</td>
<td>Mount Sinai Liver Cancer Program, Division of Liver Diseases</td>
</tr>
<tr>
<td>4:30 – 4:50pm</td>
<td>Drivers of Liver Cancer Evolution</td>
<td>Augusto Villanueva, MD</td>
<td>Mount Sinai Liver Cancer Program, Division of Liver Diseases</td>
</tr>
<tr>
<td>4:50 – 5:10pm</td>
<td>Experimental Models of Liver Cancer</td>
<td>Amaia Lujambio, PhD</td>
<td>Mount Sinai Liver Cancer Program, Department of Oncological Sciences</td>
</tr>
<tr>
<td>5:10 – 5:30pm</td>
<td>Drug Development in HCC</td>
<td>Arvin Dar, PhD</td>
<td>Department of Oncological Sciences, Department of Pharmacological Sciences</td>
</tr>
<tr>
<td>5:30pm</td>
<td>Closing Remarks</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
LIVER CANCER: NOVEL ADVANCEMENTS IN 2017

FRIDAY, DECEMBER 15, 2017

Icahn School of Medicine at Mount Sinai
Kenneth L. Davis, MD Auditorium, 2nd floor
Hess Center for Science and Medicine
1470 Madison Avenue (Between 101st and 102nd Streets)
New York, NY

Complimentary Online Registration
www.icahn.mssm.edu/cme/courses

International Attendees $100

Cancellation Policy: A 30% administrative fee will be deducted from all refunds/cancellations issued. All refund and cancellation requests must be emailed to the CME Office at cme@mssm.edu by Monday, December 4, 2017. No refunds will be made after this date or for “no-shows.”

Conference Information
www.icahn.mssm.edu/cme/courses
Office of CME at 212-731-7950
e-mail: cme@mssm.edu